CHANGES IN HEMOSTASIS IN PATIENTS WITH POST-COVID SYNDROME
Keywords:
Coronavirus-induced coagulopathy, thrombosis risk factors, hypercoagulability syndrome, disseminated intravascular coagulation syndrome.Abstract
Hemostasis disorders in COVID-19 play an important role in the pathogenesis and clinical manifestations of the disease. The ability to identify factors and risk groups for the development of thrombotic complications, interpret peripheral blood parameters and coagulograms in dynamics, knowledge of diagnostic criteria for possible hemostasis disorders (DIC syndrome, sepsis-induced coagulopathy, antiphospholipid, hemophagocytic, hypercoagulation syndromes, etc.) are necessary to determine the scope of examination, differentiated prescription of adequate therapy (including anticoagulants, blood components, plasmapheresis), which determines the greater effectiveness of complex treatment and the prognosis of patients with COVID-19.
References
Bitsadze V.O., Khizroeva D.Kh., Makatsaria A.D., Slukhanchuk E.V., Tretyakova M.V., Rizzo D., et al. COVID-19, septic shock and disseminated intravascular coagulation syndrome. Part 2. Bulletin of the Russian Academy of Medical Sciences. 2020;75(3):214–225. DOI: 10.15690/vramn1336.
Recommendations of the Moscow City Healthcare Institution for the Diagnosis and Intensive Care of Disseminated Intravascular Coagulation Syndrome in Viral Lung Infection. Edited by prof. Vorobyov P.A. and prof. Elykomov V.A. Problems of Standardization in Healthcare. 2020;5-6. DOI: 10.26347/1607-2502202005-06099-111
Galstyan GM Coagulopathy in COVID-19. Pulmonology. 2020;30(5):645–657. DOI: 10.18093/0869-0189-2020-30-5-645-657
Temporary guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" Version 9 (10.26.2020). 235 p.
Marongiu F., Grandone E., Barcellona D. Pulmonary thrombosis in 2019-nCoV pneumonia? J. Tromb. Haemost. 2020;18(6):1511– 1513. DOI: 10.1111/jth.14818.
